Potential Practice Change in Small HER2-+ Breast CancersPotential Practice Change in Small HER2-+ Breast Cancers

Less intensive chemotherapy combined with trastuzumab resulted in a very high rate of disease-free survival and suggests that more chemo is not needed in stage I disease treated with systemic therapy. Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news